Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

199 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Comparison of Treatment Completion Rate Between Conventional and Dose-dense Doxorubicin and Cyclophosphamide (AC) Followed by a Taxane in Patients With Breast Cancer: A Propensity Score-matched Analysis.
Mamishin K, Naito Y, Nomura S, Ogawa G, Niguma K, Baba K, Sakaeda S, Nakajima H, Kusuhara S, Funasaka C, Nakao T, Fukasawa Y, Kondoh C, Harano K, Kogawa T, Matsubara N, Hosono A, Kawasaki T, Mukohara T. Mamishin K, et al. Among authors: hosono a. Anticancer Res. 2021 Dec;41(12):6217-6224. doi: 10.21873/anticanres.15441. Anticancer Res. 2021. PMID: 34848476
Comparison of dose intensity of vincristine, d-actinomycin, and cyclophosphamide chemotherapy for child and adult rhabdomyosarcoma: a retrospective analysis.
Kojima Y, Hashimoto K, Ando M, Yonemori K, Yamamoto H, Kodaira M, Yunokawa M, Shimizu C, Tamura K, Hosono A, Makimoto A, Fujiwara Y. Kojima Y, et al. Among authors: hosono a. Cancer Chemother Pharmacol. 2012 Sep;70(3):391-7. doi: 10.1007/s00280-012-1920-0. Epub 2012 Jul 18. Cancer Chemother Pharmacol. 2012. PMID: 22806306
Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.
Matsubara N, Mukai H, Hosono A, Onomura M, Sasaki M, Yajima Y, Hashizume K, Yasuda M, Uemura M, Zurth C. Matsubara N, et al. Among authors: hosono a. Cancer Chemother Pharmacol. 2017 Dec;80(6):1063-1072. doi: 10.1007/s00280-017-3417-3. Epub 2017 Aug 11. Cancer Chemother Pharmacol. 2017. PMID: 28801852 Free PMC article. Clinical Trial.
Erratum to: Phase 1 study of darolutamide (ODM-201), a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer.
Matsubara N, Mukai H, Hosono A, Onomura M, Sasaki M, Yajima Y, Hashizume K, Yasuda M, Uemura M, Zurth C. Matsubara N, et al. Among authors: hosono a. Cancer Chemother Pharmacol. 2017 Dec;80(6):1073-1077. doi: 10.1007/s00280-017-3433-3. Cancer Chemother Pharmacol. 2017. PMID: 29063294 Free PMC article. No abstract available.
Multimodal treatment including standard chemotherapy with vincristine, doxorubicin, cyclophosphamide, ifosfamide, and etoposide for the Ewing sarcoma family of tumors in Japan: Results of the Japan Ewing Sarcoma Study 04.
Chin M, Yokoyama R, Sumi M, Okita H, Kawai A, Hosono A, Koga Y, Sano H, Watanabe H, Ozaki T, Mugishima H; Japan Ewing Sarcoma Study Group (JESS). Chin M, et al. Among authors: hosono a. Pediatr Blood Cancer. 2020 May;67(5):e28194. doi: 10.1002/pbc.28194. Epub 2020 Feb 20. Pediatr Blood Cancer. 2020. PMID: 32077253 Clinical Trial.
Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.
Mukohara T, Hosono A, Mimaki S, Nakayama A, Kusuhara S, Funasaka C, Nakao T, Fukasawa Y, Kondoh C, Harano K, Naito Y, Matsubara N, Tsuchihara K, Kuwata T. Mukohara T, et al. Among authors: hosono a. Oncologist. 2021 Aug;26(8):635-639. doi: 10.1002/onco.13715. Epub 2021 Mar 11. Oncologist. 2021. PMID: 33559918 Free PMC article.
199 results